Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
Portfolio Pulse from
Shuttle Pharmaceuticals Holdings, Inc. has expanded patient enrollment for its Phase 2 clinical trial of Ropidoxuridine, a treatment for glioblastoma, with the first patient dosed at UVA Cancer Center. This trial is being conducted at six cancer centers, including Miami Cancer Institute.
November 26, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shuttle Pharmaceuticals has expanded its Phase 2 clinical trial for Ropidoxuridine, a potential treatment for glioblastoma, with the first patient dosed at UVA Cancer Center. This development could positively impact SHPH's stock as it progresses in cancer treatment research.
The expansion of the clinical trial and the dosing of the first patient at a reputable cancer center like UVA indicates progress in Shuttle Pharma's research efforts. This could lead to positive investor sentiment and a potential increase in stock price as the company advances in its clinical trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100